Sanofi (SNY) Capital Expenditures (2009 - 2021)
Sanofi (SNY) posted Capital Expenditures of -$101.4 million for Q4 2021, up 3.84% sequentially from -$105.4 million in Q4 2020, and up 3.84% YoY from -$97.6 million in Q4 2020.
Sanofi (SNY) Capital Expenditures (2009 - 2021) Analysis & Trends
Sanofi has reported Capital Expenditures for 4 years, with the latest figure at -$101.4 million in Q4 2021.
- Quarterly Capital Expenditures rose 3.84% year-over-year to -$101.4 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$2.9 billion (down 318.12% YoY) and the FY2025 annual result came in at $4.1 billion, up 20.63% from the prior year.
- Capital Expenditures improved to -$101.4 million in Q4 2021 per SNY's latest filing, from -$105.4 million in the prior quarter.
- Over five years, Capital Expenditures peaked at -$90.5 million in Q4 2019 and troughed at -$105.4 million in Q4 2020.
- A 3-year average of -$99.1 million and a median of -$101.4 million in 2021 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2020 and 2021: Capital Expenditures decreased 16.41% in 2020, then grew 3.84% in 2021.
- Over 3 years, Capital Expenditures stood at -$90.5 million in 2019, then retreated by 16.41% to -$105.4 million in 2020, then climbed by 3.84% to -$101.4 million in 2021.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$101.4 million, -$105.4 million, and -$90.5 million for Q4 2021, Q4 2020, and Q4 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -101.36 Mn |
| Dec 31, 2021 | -101.36 Mn |
| Dec 31, 2020 | -105.40 Mn |
| Dec 31, 2020 | -105.40 Mn |
| Dec 31, 2019 | -90.54 Mn |
| Dec 31, 2019 | -90.54 Mn |
| Dec 31, 2009 | -2.64 Bn |
| Dec 31, 2009 | -2.64 Bn |